NCT05700422View on ClinicalTrials.gov

Nasal Spray Study in Sjogren's Dry Eye Disease

PHASE4CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions

Sjogren's SyndromeDry Eye

Interventions

DRUG

Varenicline Nasal Spray

OC-01 (varenicline solution) 0.03 mg nasal spray

Trial Locations (1)

19104

Scheie Eye Institute at the University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Oyster Point Pharma, Inc.

All Listed Sponsors

collaborator

Oyster Point Pharma, Inc.

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT05700422 - Nasal Spray Study in Sjogren's Dry Eye Disease | Biotech Hunter | Biotech Hunter